Buchumschlag

Analysis of soluble interleukin-2 receptor as a prognostic biomarker in NMOSD and MOGAD

Objective Soluble interleukin-2 receptor (sIL-2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) pathogenesis. However, sIL-2R has so far not been evaluated in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Klyscz, Philipp (VerfasserIn) , Otto, Carolin (VerfasserIn) , Ruprecht, Klemens (VerfasserIn) , Asseyer, Susanna (VerfasserIn) , Tiedt, Hannes Ole (VerfasserIn) , Meisel, Christian (VerfasserIn) , Bellmann-Strobl, Judith (VerfasserIn) , Paul, Friedemann (VerfasserIn) , Schindler, Patrick (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: December 2025
In: Annals of Clinical and Translational Neurology
Year: 2025, Jahrgang: 12, Heft: 12, Pages: 2460-2469
ISSN:2328-9503
DOI:10.1002/acn3.70186
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/acn3.70186
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/acn3.70186
Volltext
Verfasserangaben:Philipp Klyscz, Carolin Otto, Klemens Ruprecht, Susanna Asseyer, Hannes Ole Tiedt, Christian Meisel, Judith Bellmann-Strobl, Friedemann Paul, Patrick Schindler
Beschreibung
Zusammenfassung:Objective Soluble interleukin-2 receptor (sIL-2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) pathogenesis. However, sIL-2R has so far not been evaluated in these conditions. Here, we compared sIL-2R levels in serum and cerebrospinal fluid (CSF) of patients with aquaporin-4-IgG-seropositive and seronegative (AQP4-IgG+/−) NMOSD, MOGAD, and noninflammatory neurologic disorders (NINDs), and assessed the prognostic value of sIL-2R for future attacks. Methods Retrospective analysis of real-world data of patients treated at Charité—Universitätsmedizin Berlin was conducted (45 MOGAD, 14 AQP4-IgG+NMOSD, 10 AQP4-IgG−NMOSD, 69 NINDs) between 2010 and 2024. Mean (SD) follow-up time was 40 (35) months. sIL-2R differences were assessed by linear mixed models. Cox regression analysis was performed to investigate the predictive value for subsequent attacks. Results Serum sIL-2R was higher in AQP4-IgG+NMOSD (estimated marginal mean [EMM] 802 IU/mL) and MOGAD (569 IU/mL) compared to NINDs (404 IU/mL). In patients with a first manifestation of MOGAD, but not NMOSD, serum sIL-2R (HR = 9.07 [95% CI 1.37-60.01]) and CSF sIL-2R (HR = 3.27 [95% CI 0.61-17.45]) levels were predictive for subsequent attacks. Interpretation Serum sIL-2R is elevated in AQP4-IgG+NMOSD and MOGAD and may be a prognostic biomarker for a relapsing disease course in MOGAD.
Beschreibung:Online verfügbar: 05. September 2025
Gesehen am 29.01.2026
Beschreibung:Online Resource
ISSN:2328-9503
DOI:10.1002/acn3.70186

Ähnliche Einträge